Form 4: Achieve Life Sciences Director Kristen B. Slaoui Acquires Stock Options

Director Kristen B. Slaoui of Achieve Life Sciences acquired stock options for 47,250 shares on January 13, 2025.

Summary

• Kristen B. Slaoui, a director at Achieve Life Sciences, was granted stock options to purchase 47,250 shares of common stock.
• The options have an exercise price of $3.32 per share.
• The options vest in equal monthly installments over 36 months, starting January 6, 2025, contingent on continued service to the company.
• The options expire on January 13, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The granting of stock options to a director aligns their interests with the company's long-term success.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The director's stock options will vest over the next 36 months, contingent on continued service.

Industry Context

Stock option grants are a common practice for incentivizing directors and aligning their interests with shareholders in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the biotechnology industry, similar to companies like Gilead Sciences and Amgen.
• The vesting schedule of 36 months is also typical, aligning with long-term performance goals.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially leading to increased focus on long-term value creation.

Key Dates

Keywords

stock options, director, insider trading, equity, vesting, Achieve Life Sciences